2 Numbers in Merck's 4th-Quarter Report That Have Investors Worried
Merck may have surpassed Wall Street's profit forecast, but these two numbers suggest that growth may be challenged in 2016.
Novo Nordisk A/S Taps the Growth Brakes
The diabetes specialist expects to see slowing operating growth, but it has a good reason.
ImmunoGen, Inc.'s Earnings Play the Amortization Blues
Keep focused on the pipeline because revenue and earnings are going to be bumpy for some time.
3 Numbers That Matter When Merck Reports Its Fourth-Quarter Results
These three figures may prove far more important than Merck's fourth-quarter and full-year headline results.